We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
Read MoreHide Full Article
Key Takeaways
RCKT posted Q4 loss of 38 cents per share, beating estimates, while no revenues were reported.
Rocket Pharmaceuticals' resubmitted BLA for Kresladi in LAD-I faces an FDA decision on March 28, 2026.
RCKT expects cash runway into Q2 2027 as the RP-A501 study in Danon disease resumes in H1 2026.
Rocket Pharmaceuticals (RCKT - Free Report) incurred a loss of 38 cents per share in the fourth quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 42 cents. In the year-ago quarter, the company reported a loss of 62 cents per share.
In the absence of a marketed product in its portfolio, Rocket Pharmaceuticals did not record any revenues in the fourth quarter.
Shares of Rocket Pharmaceuticals were up 6.4% in after-hours trading yesterday following the announcement of the earnings results.
The stock has surged 36.7% in the past six months compared with the industry’s rise of 22.4%.
Image Source: Zacks Investment Research
RCKT’s Q4 Results in Detail
In the reported quarter, general and administrative expenses declined around 42% year over year to $14.7 million.
Research and development expenses were $29.3 million, down 21.6% from the year-ago quarter’s figure. The decrease reflects more disciplined spending and resource management after the company’s recent organizational restructuring.
As of Dec. 31, 2025, Rocket Pharmaceuticals had cash, cash equivalents and investments of $188.9 million compared with $222.8 million as of Sept. 30, 2025. Management expects this cash balance to fund operations and meet capital expenditure requirements into the second quarter of 2027.
RCKT's Full-Year Results
For 2025, the company recorded a loss of $2.01 per share, which was narrower than a loss of $2.73 reported in the year-ago period.
The company did not record any revenues in 2025.
RCKT’s Encouraging Pipeline Progress
In October 2025, Rocket Pharmaceuticals received a major boost when the FDA accepted the resubmitted biologics license application (BLA) seeking approval for its gene therapy Kresladi (marnetegragene autotemcel; marne-cel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
A decision from the regulatory body on the BLA is expected on March 28, 2026.
If Kresladi is eventually approved by the FDA, the company will be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV) — an incentive given by the FDA to encourage the development of drugs and biologics for rare and serious diseases.
Also, last August, the FDA lifted the clinical hold on the pivotal phase II study evaluating RCKT’s investigational gene therapy candidate, RP-A501, for treating patients with Danon disease. RP-A501 is the most advanced AAV-based candidate in the company’s pipeline.
Per an agreement with the FDA, three more patients will receive treatment with a lower, recalibrated dose of RP-A501 (3.8 x 10¹³ GC/kg), with a minimum four-week interval between doses and an updated immune-modulating regimen. The pivotal phase II study on RP-A501 is expected to resume in the first half of 2026.
Rocket Pharmaceuticals is also developing RP-A601 in an early-stage study for treating arrhythmogenic cardiomyopathy. The company also plans to start clinical studies on a new gene therapy candidate, RP-A701, for the treatment of dilated cardiomyopathy by mid-2026.
Rocket Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Over the past 60 days, Castle Biosciences’ 2026 loss per share estimates have narrowed from $1.06 to 96 cents. CSTL’s shares have rallied 54.6% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.08 to $8.22. ANIP’s shares have fallen 15.9% in the past six months.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 21.24%.
Over the past 60 days, estimates for Arcus Biosciences’ 2026 loss per share have narrowed from $3.90 to $3.86. RCUS’ shares have soared 88.2% in the past six months.
Arcus Biosciences’ earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 28.14%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
Key Takeaways
Rocket Pharmaceuticals (RCKT - Free Report) incurred a loss of 38 cents per share in the fourth quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 42 cents. In the year-ago quarter, the company reported a loss of 62 cents per share.
In the absence of a marketed product in its portfolio, Rocket Pharmaceuticals did not record any revenues in the fourth quarter.
Shares of Rocket Pharmaceuticals were up 6.4% in after-hours trading yesterday following the announcement of the earnings results.
The stock has surged 36.7% in the past six months compared with the industry’s rise of 22.4%.
Image Source: Zacks Investment Research
RCKT’s Q4 Results in Detail
In the reported quarter, general and administrative expenses declined around 42% year over year to $14.7 million.
Research and development expenses were $29.3 million, down 21.6% from the year-ago quarter’s figure. The decrease reflects more disciplined spending and resource management after the company’s recent organizational restructuring.
As of Dec. 31, 2025, Rocket Pharmaceuticals had cash, cash equivalents and investments of $188.9 million compared with $222.8 million as of Sept. 30, 2025. Management expects this cash balance to fund operations and meet capital expenditure requirements into the second quarter of 2027.
RCKT's Full-Year Results
For 2025, the company recorded a loss of $2.01 per share, which was narrower than a loss of $2.73 reported in the year-ago period.
The company did not record any revenues in 2025.
RCKT’s Encouraging Pipeline Progress
In October 2025, Rocket Pharmaceuticals received a major boost when the FDA accepted the resubmitted biologics license application (BLA) seeking approval for its gene therapy Kresladi (marnetegragene autotemcel; marne-cel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
A decision from the regulatory body on the BLA is expected on March 28, 2026.
If Kresladi is eventually approved by the FDA, the company will be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV) — an incentive given by the FDA to encourage the development of drugs and biologics for rare and serious diseases.
Also, last August, the FDA lifted the clinical hold on the pivotal phase II study evaluating RCKT’s investigational gene therapy candidate, RP-A501, for treating patients with Danon disease. RP-A501 is the most advanced AAV-based candidate in the company’s pipeline.
Per an agreement with the FDA, three more patients will receive treatment with a lower, recalibrated dose of RP-A501 (3.8 x 10¹³ GC/kg), with a minimum four-week interval between doses and an updated immune-modulating regimen. The pivotal phase II study on RP-A501 is expected to resume in the first half of 2026.
Rocket Pharmaceuticals is also developing RP-A601 in an early-stage study for treating arrhythmogenic cardiomyopathy. The company also plans to start clinical studies on a new gene therapy candidate, RP-A701, for the treatment of dilated cardiomyopathy by mid-2026.
Rocket Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Rocket Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Rocket Pharmaceuticals, Inc. Quote
RCKT's Zacks Rank & Stocks to Consider
Rocket Pharmaceuticals currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Castle Biosciences (CSTL - Free Report) , ANI Pharmaceuticals (ANIP - Free Report) and Arcus Biosciences (RCUS - Free Report) . While Castle Biosciences currently sports a Zacks Rank #1 (Strong Buy), ANI Pharmaceuticals and Arcus Biosciences hold a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, Castle Biosciences’ 2026 loss per share estimates have narrowed from $1.06 to 96 cents. CSTL’s shares have rallied 54.6% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.08 to $8.22. ANIP’s shares have fallen 15.9% in the past six months.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 21.24%.
Over the past 60 days, estimates for Arcus Biosciences’ 2026 loss per share have narrowed from $3.90 to $3.86. RCUS’ shares have soared 88.2% in the past six months.
Arcus Biosciences’ earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 28.14%.